Skip to main content
Premium Trial:

Request an Annual Quote

TurboWorx Reshuffles Brass; CeMines Hires Invitrogen and Qiagen Alumni; ABI s Bob Jones Lands at Fluidigm; Solexa Taps Wellcome Vet for Chief Science Slot; and Others

Pauline Gee has become vice president and general manager, and Anosheh Amery vice president of sales and marketing of the biosystems division of CeMines, the company said yesterday.


Gee joins CeMines from MDS Pharma Services, where she was vice president of predictive biology, responsible for directing the company's chemogenomics and toxicogenomics efforts. She holds a PhD in free radical chemistry from Simon Fraser University in British Columbia, Canada.


Amery comes to CeMines from Invitrogen, where he directed the launch of more than 15 new products and managed the evaluation and strategic planning of new business opportunities. Prior to Invitrogen, Amery was at Qiagen. He holds a bachelor of science degree in Physiological Sciences from UCLA and an MBA from SDA Bocconni in Milan, Italy.

Robert Jones has become executive vice president of R&D for Fluidigm, the South San Francisco, Calif.-based company said yesterday. He joins the company from Applied Biosystems, where he was most recently senior vice president of product research and development, directing product development for all genomics, proteomics and informatics platforms. Jones holds BSEE and MSEE degrees in computer engineering from the Universityof Washington.

Srini Chari has become president and CEO of TurboWorx, replacing former president Jeff Augen, who resigned for medical reasons, the Shelton, Conn.-based company said yesterday. Chariwas TurboWorx's solutions vice president and general manager for the last year. Prior to joining the company, he was program director for emerging businesses in the corporate strategy organization at IBM.


Chariholds an MBA from the Stern School of Business at New York University, a PhD in computational mechanics and engineering from the Universityof Texas, and a bachelor's degree in mechanical engineering from the Indian Institute of Technology in Madras, India.


Further, Andrew Sherman, a company founder, was promoted to TurboWorx's vice president of development and chief technical officer. Previously, he was responsible for technical product R&D and internal operations. Shermanholds a PhD in computer science from YaleUniversity.


Former marketing director Jason Alter has been promoted to vice president of marketing and professional services. He joined TurboWorx in March. Alter received a PhD in molecular biology from Binghamton University and holds an MS in microbiology from Texas A&M University


Gourish Hosangady, formerly vice president of channels and alliances, has been appointed vice president of sales. He joined TurboWorx in 2004. Hosangady has a master's degree in engineering from the Universityof Missouriand a bachelor's degree in engineering from the Indian Institute of Technology.


Finally, Mary Anne Sulik has become chief financial officer and vice president of business operations. She holds a BS in accounting from Sacred Heart University and an MBA in taxation from TulaneUniversity.

Dennis Langer has been appointed to the board of directors of Sirna Therapeutics, the company said yesterday. He is a managing partner of Phoenix IP Ventures, a venture capital firm in Philadelphia. Langer has an MD from Georgetown University School of Medicine, a JD from Harvard Law School, and a BA in biology from ColumbiaUniversity. He also serves on the boards of Myriad Genetics and Cytogen.

Gordon Foulkes has become a venture partner of RiverVest Venture Partners, the St. Louis-based company said on Monday. Also, Scott Naisbitt has been promoted to principal.


Prior to joining RiverVest, Foulkes was chief scientific officer and member of the board of directors at Oncogene Science (OSI Pharmaceuticals). He received a PhD in biochemistry from the Universityof Dundee, Scotland, and a BSc in biochemistry from the UniversityCollegeCardiff.

David Bentley will join Solexa as chief scientist on Sept. 5, the company said on Monday. He comes to Solexa from the Wellcome Trust Sanger Institute, where he was a founding member of the management team, holding the position of head of human genetics. At Solexa, Bentley will spearhead the company's DNA sequencing applications development and projects. He has been on Solexa's scientific advisory board since 1998 and is a co-inventor of aspects of the company's technology. Bentley holds a DPhil from the Universityof Oxfordand an MA in biochemistry from the Universityof Cambridge.

Mark Whitman has joined the scientific advisory board of CombiMatrix Molecular Diagnostics, the company said on Monday. He will also be a company consultant in the area of melanoma diagnosis and management. Whitman is the administrative director of surgical services and the director of the melanoma center at MountainsideHospitalin Montclair, New Jersey. He holds a medical degree from Pennsylvania State University School of Medicine and a BA in chemistry from HaverfordCollege.

Thomas Tombrello has joined the scientific advisory board of Arrowhead Research, the parent company of RNAi drugs startup Calando Pharmaceuticals. Tombrello is chairman of the division of physics, mathematics, and astronomy at the California Institute of Technology as well as the institute's technology assessment officer.


Anders Åberg has become chief scientific officer of Sidec Technologies, the Stockholm, Sweden-based company said last week. He comes to Sidec from AstraZeneca, where he was director of the structural chemistry laboratory. Åberg holds a PhD in molecular biology from StockholmUniversity.

Michael Terry, executive vice president of sales and marketing at Sequenom, has left the company on July 25, the company said in an SEC filing. He will remain available to "provide reasonable consulting services," Sequenom said.

Nonlinear Dynamics has appointed Ian Currie as European sales manager. Ian joins Nonlinear from Amersham Biosciences (now part of GE Healthcare) where he was project manager for the development of the DeCyder software.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.